Sutro Biopharma, Inc.
Clinical trials sponsored by Sutro Biopharma, Inc., explained in plain language.
-
New hope for tough ovarian cancer? trial tests targeted drug vs standard chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin against standard chemotherapy in about 600 women whose ovarian cancer had stopped responding to platinum-based treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated ear…
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Ovarian cancer drug combo trial halted early
Disease control TerminatedThis early-phase study tested a new drug (STRO-002) combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal was to check safety and find the right dose. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 19, 2026 11:47 UTC